Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
10/2005
10/27/2005US20050239858 Pyrazole derivatives as gnrh inhibitors
10/27/2005US20050239857 Novel imidazoles
10/27/2005US20050239855 For therapy of cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
10/27/2005US20050239843 Diaminothiazoles
10/27/2005US20050239841 New compounds
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239829 Novel piperidine compound
10/27/2005US20050239828 Spirocyclic amides as cannabinoid receptor modulators
10/27/2005US20050239827 N-(4-(2,2-difluoro-benzo(1,3)dioxol-5-ylcarbamoyl)-3-hydroxy-phenyl)-4,6-Bis-((3R,5S)-3,5-diamino-piperidin-1-yl)-(1,3,5)triazine-2-amine for example; Gram-positive and Gram-negative strains; retains potency against common antibiotic resistant strains
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239812 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
10/27/2005US20050239811 Tri-substituted ureas as cytokine inhibitors
10/27/2005US20050239810 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
10/27/2005US20050239808 Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
10/27/2005US20050239801 Novel compounds
10/27/2005US20050239800 Polycyclic pyrazines as potassium ion channel modulators
10/27/2005US20050239797 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity
10/27/2005US20050239796 tert-butyl4-{(3,4-dimethoxyphenethyl)[2-(1H-indol-3-yl)acetyl]amino}-1-piperidine carboxylate; somatostatin receptors modulator; anticarcinogenic agent; acromegalia, hypophyseal adenomas, endocrine gastroenteropancreatic tumors including carcinoid syndrome; reducing amination of N-substituted piperidone
10/27/2005US20050239791 Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
10/27/2005US20050239786 Triazole derivatives as tachykinin receptor antagonists
10/27/2005US20050239782 Arylindenopyridines and related therapeutic and prophylactic methods
10/27/2005US20050239777 Quinazoline derivatives and pharmaceutical compositions containing them
10/27/2005US20050239776 Tachykinin receptor antagonists
10/27/2005US20050239775 Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression
10/27/2005US20050239771 Respiratory syncytial virus replication inhibitors
10/27/2005US20050239770 e.g. 3-{4-Cyclopentylamino-6-[(2,2-dimethyl-propyl)-methyl-amino]-pyrimidin-2-ylamino}-4-methyl-benzamide; via p38 kinase inhibition; (anilino)(halo)pyrimidine or (anilino)(amino)pyrimidine derivatives; rheumatoid arthritis, psoriasis, Crohn's Disease, osteoarthritis or osteoporosis
10/27/2005US20050239054 Drug screening compounds having esterified phosphonate or carboxyl groups with novel enzyme GS-7340 Ester Hydrolase and identifying the compound as a suitable prodrug by the formation of a phosphonic acid or carboxylic acid; candidate compounds
10/27/2005US20050238916 Light sources comprising organic light emmiters between electrodes, used in displaying, electrophotography, recording, exposure, signs or optical communications; brightness; efficiency; durability; iridium complex
10/27/2005US20050238614 Polyethylene glycol conjugates of heterocycloalkyl carboxamido propanoic acids
10/27/2005US20050236980 Charge transport compositions and electronic devices made with such compounds
10/27/2005US20050236974 Condensed polycyclic compound and organic light-emitting device using the same
10/27/2005DE102004018795A1 Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel Selected CGRP antagonists, processes for their preparation and their use as medicaments
10/27/2005CA2563386A1 Selected cgrp-antagonists, their preparation processes and their use as medicaments
10/27/2005CA2563225A1 Process for preparing pyridazinone compounds
10/27/2005CA2562846A1 Sulphur-linked imidazole compounds for the treament of hiv
10/27/2005CA2562602A1 2-aminopyridine derivative
10/27/2005CA2562526A1 Selected cgrp antagonists, method for producing the same and the use thereof as drugs
10/27/2005CA2562235A1 Piperazinylpiperidine derivatives as chemokine receptor antagonists
10/27/2005CA2562132A1 17 beta-acetamide-4-azasteroids as androgen receptor modulators
10/27/2005CA2561895A1 Polycyclic pyrimidines as potassium ion channel modulators
10/27/2005CA2561718A1 Polycyclic pyridines as potassium ion channel modulators
10/27/2005CA2561564A1 Pgd2 receptor antagonists for the treatment of inflammatory diseases
10/27/2005CA2561311A1 Inhibitors of akt activity
10/27/2005CA2560346A1 Polycyclic pyridines as potassium ion channel modulators
10/26/2005EP1589013A2 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/26/2005EP1588727A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588726A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
10/26/2005EP1588701A2 Rapidly-decomposing dosage form for releasing nicotine in the oral cavity or in bodily cavities
10/26/2005EP1588145A2 Methods, mixtures, kits and compositions pertaining to analyte determination
10/26/2005EP1587877A1 Beta-isoindigo coloring agent
10/26/2005EP1587804A1 Androgen receptor antagonists
10/26/2005EP1587803A1 Pyrimidine-4,6-dicarboxylic acid diamides for use as selective mmp 13 inhibitors
10/26/2005EP1587795A1 N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivatives and related compounds use as cgrp-antagonists for treating a headache
10/26/2005EP1587790A2 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
10/26/2005EP1587788A1 2,7-substituted indoles and their use as 5-ht6 modulators
10/26/2005EP1587787A1 Viral polymerase inhibitors
10/26/2005EP1587585A1 Acylsulfonamide compounds as inhibitors of rna-dependent rna (viral) polymerases
10/26/2005EP1587529A2 Antibacterial compounds having a (pyrrole carboxamide)-(benzamide)-(imidazole carboxamide) motif
10/26/2005EP1587509A2 Androgen receptor antagonists
10/26/2005EP1587473A2 Thiosemicarbazones as anti-virals and immunopotentiators
10/26/2005EP1441683A4 Trisubstituted triazine compounds, and methods for making an using the compounds, which have antitubulin activity
10/26/2005EP1427408A4 CYCLIC HYDROXAMIC ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-$g(a) CONVERTING ENZYME (TACE)
10/26/2005EP1410019B1 Cardiovascular safety assay
10/26/2005EP1397354B1 Imidazole-2-carboxamide derivatives as raf kinase inhibitors
10/26/2005EP1341766B1 Imidazolone derivatives for the treatment of viral diseases
10/26/2005EP1289965B1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
10/26/2005EP1131312B1 Novel pyrimidine derivatives and processes for the preparation thereof
10/26/2005EP1129071B1 Phenyl-substituted cyclic enaminones
10/26/2005EP1098870B1 Nitrate salt of Cetirizine
10/26/2005EP1025847B1 Neovascularization promoters and neovascularization potentiators
10/26/2005EP0835245B1 Substituted n-methylenethioureas as pesticides
10/26/2005EP0762880B1 Retroviral protease inhibitor combinations
10/26/2005CN1688574A Indole-3-carboxamides as glucokinase(GK) activators
10/26/2005CN1688573A Pyrrole based inhibitors of glycogen synthase kinase 3
10/26/2005CN1688572A Piperidinyl targeting compounds that selectively bind integrins
10/26/2005CN1688571A Substituted heterocyclylpyrimidines
10/26/2005CN1688570A Novel synthesis of gatifloxacin
10/26/2005CN1688555A Novel bicyclic inhibitors of hormone sensitive lipase
10/26/2005CN1688554A 1, 2, 4-triazole derivative, method for preparing the same, and pharmaceutical composition containing the same
10/26/2005CN1688552A Pyrimidine derivatives and their use as CB2 modulators
10/26/2005CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
10/26/2005CN1688549A Compound having TGF-beta inhibitory activity and medicinal composition containing the same
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688545A Phosphodiesterase 4 inhibitors, including n-substituted phenylamine and diphenylamine analogs
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224622C Method for preparing 2-alkyl-3-aminothiophene derivative and 3-aminothiophene derivative
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/25/2005US6958402 3-(imidazolyl)-2-alkoxypropanoic acids
10/25/2005US6958356 Guanidine mimics factor Xa inhibitors
10/25/2005US6958354 Pyrazole compounds as transforming growth factor (TGF) inhibitors
10/25/2005US6958353 Imidazole derivatives or salts thereof and drugs containing the derivatives or the salts
10/25/2005US6958350 Chemical compounds
10/25/2005US6958349 Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/25/2005US6958348 Side effect reduction
10/25/2005US6958347 Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
10/25/2005US6958346 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
10/25/2005US6958340 such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene
10/25/2005US6958339 Pyrazole derivative
10/25/2005US6958338 E.g., 5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-indole; partial agonists or antagonist at the dopamine D4 receptors; psychoses, schizophrenia, cognition activators; attention deficit disorder; dyskinesia; side effects reduction
10/25/2005US6958335 Use of imatinib, 4-(4-methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-y l) pyrimidin-2-ylamino)phenyl)-benzamide or a pharmaceutically acceptable salt
1 ... 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 ... 1080